Industry scope 

1. Monoclonal antibodies, which are engineered proteins that can target specific proteins or cells in the body. They are used to treat a range of diseases, including cancer, autoimmune disorders, and infectious diseases 
2. Protein therapeutics used to replace or supplement proteins that are deficient or malfunctioning in the body, such as insulin to treat diabetes
3. RNA-based therapeutics used to target specific RNA molecules in the body, either to silence or replace them, such as messenger RNA (mRNA)-based vaccines for preventing infectious diseases such as Covid-19
4. Antibody-drug conjugates (ADCs) that combine the targeting ability of monoclonal antibodies with the cytotoxic effects of chemotherapy drugs

1. Gene Therapies, as it involves the direct manipulation of a patient's genetic material, typically using viruses or other vectors to deliver therapeutic genes to cells in the body. Gene therapies do not involve giving a patient a chemical or biological substance that was created outside of their body. Instead, they aim to change the patient's genetic code to treat disease and are often considered to be a separate category of treatment
2. Biosimilars, which are very similar to existing approved reference products (i.e., an original biologic drug). These are covered in a separate hub
3. Precision Medicine treatments that are focused on small-molecule drugs